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In the context of current clinical practice guidance, this paper will analyse the role of GPs in
decision-making about the primary prevention of cardiovascular disease (CVD) using the
concept of pharmaceuticalisation. Drawing on thematic analysis of semi-structured
interviews with 20 GPs, the paper argues that the way GPs approach CVD
pharmaceuticalisation is shaped by their understandings of and use of guidelines (and
the knowledge they embody), existing treatment perspectives and the moral qualities of
preventative treatment, and professional evaluations of ‘relevant’ information. The analysis
indicates that there exist disparate and distinct approaches to and understandings of CVD
pharmaceuticalisation amongst GPs. Depending on how knowledge, treatment
perspectives and values variously combine, GPs sit somewhere on a spectrum of how
pharmaceuticalised they are in terms of the approaches to and understandings of the
prevention of CVD.
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INTRODUCTION
Under current clinical practice guidance known as CG181 (NICE, 2014a), produced by the National
Institute for Health and Care Excellence (NICE), general practitioners (GPs) in England are directed to
offer advice on prophylactic measures when a patient has a ≥10% risk over ten years of developing
cardiovascular disease. Importantly, this includes offering the class of pharmaceuticals namedHMG-CoA
reductase inhibitors, or as they are more widely known, statins, to try to prevent CVD. The drugs aim to
reduce low-density lipoprotein (LDL) cholesterol (‘bad cholesterol’), an important risk factor for CVD.
However, risk calculation also takes into account sex, family history, ethnicity, modifiable lifestyle risk
factors such as smoking, blood pressure, and geographical factors such as whether an individual lives in
the north or south of England (National Clinical Guideline Centre (NCGC), 2014: 5). These risk factors
are in part bound up together. For example, modifiable lifestyle risk factors contribute to cholesterol levels
in most cases of high cholesterol, and broadly statins can be thought of as ‘risk reducers’ that are
prescribed because of overall risk calculation and strategy.When looking at these factors, if the risk profile
of an individual is 10% over ten years, this means that in the next ten years from a group of 100 similar
people ten would have, for example, a heart attack or stroke. However, if all of those 100 took a statin four
of those ten would be prevented from having that heart attack or stroke (NICE, 2014b).
The use of these drugs in the primary prevention of CVD has been viewed in some professional
and popular discourse as controversial. As what is considered unacceptable levels of risk have
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expanded, there has been debate about benefit and safety in
medical circles. Indeed, there was a high-profile medical dispute,
covered widely by national British newspapers in 2014, when the
most recent NICE clinical practice guidance (CG181) was
published. This latest guidance halved the risk threshold from
≥20 to ≥10% risk over ten years, making millions more people
eligible for statins. This guidance ran contrary to the fact that
some other analysis suggests that the safety and efficacy of statins
may be questionable at lower levels of risk (see Abramson et al.,
2013). Indeed, there have been concerns about pharmaceutical
industry funding of research forming the evidence base and
hidden trial data (Godlee, 2016)—which are well-established
criticisms of the industry generally (Lexchin et al., 2003).
Additionally, there were concerns that those on NICE’s
purportedly independent Guideline Development Group
(GDG) might have links to the pharmaceutical industry (Wise,
2014). Concerns surrounding promoting healthy lifestyles, or
what might be termed lifestylism (Hansen and Easthope, 2007),
which refers to the emphasis on the individual responsibility for
ensuring health through the adoption of ‘healthy’ lifestyle
practices (e.g., diet, exercise, smoking cessation), also encircled
the guideline’s publication—notions which exist uneasily
alongside widening deployment of statins to lower thresholds
of risk (Polak, 2017). Though lifestyle recommendations were
also made in CG181, with NICE suggesting that lifestyle risk
factors should be modified alongside and/or prior to the initiation
of a statin, the centrality of statins to NICE’s recommendation
was problematised in both professional circles and in the mass
media on the grounds that it did not do enough to challenge
unhealthy lifestyle practices. The controversy was so significant
that NICE were forced to abandon attempts to include patients
with a calculated risk within the new primary prevention risk
threshold in the Quality and Outcomes Framework (QOF). This
meant that GPs (at the time of the data collection for this
research) were not monitored or incentivised to prescribe
statins to these new patients in the same way as patients with
higher levels of risk.
It is worth noting that this case exists in a broader context of
debate and controversy about evidence based medicine (EBM).
The EBMmovement emerged in earnest in the 1990s, attempting
to make medical practice more scientific (and cost-effective) by
grounding it in randomised controlled trial (RCT) evidence
rather than more idiosyncratic experience or tradition. This
approach assumes that valid evidence is obtained from
expertly produced and accumulated research rooted in a
hierarchy of evidence (with RCTs the gold standard). The
model tends to view GPs as too busy to access and/or
insufficiently skilled to interpret and use this best available
evidence in their practice. As such, this knowledge is
disseminated to them through guidelines, with professional
practice expected to be subsequently shaped/modified in line
with the guidance (Harrison et al., 2002: 4–6). Though EBM is
now dominant, there are general concerns, argue Greenhalgh
et al. (2014), that vested interests distort evidence, that the
amount of evidence (particularly in the form of clinical
practice guidelines) is now intractable, that increasing focus on
statistical significance and risk of disease can mean that gains are
marginal, and that guidelines do not always map well onto the
individual clinical consultation and crowd out clinical expertise to
the detriment of shared decision-making and patient care. ‘Real’
EBM, argue these authors, actually involves individualising
evidence for the patient, is based on judgement rather than
strict adherence to guidelines, is rooted in strong interpersonal
relationships between patients and clinicians, and across these
aspects, centres on ethical judgements and shared decision-
making. There are clear tensions then, between the RCT
model of EBM, which NICE guidelines embody, and other
approaches which valorise holistic and individualised
medical care.
In the context of the latest clinical practice guidance produced
by NICE, this paper analyses the perspectives and understandings
of GPs about the prophylactic treatment of CVD. It focuses
particularly on the approaches of GPs to preventative
treatment in the newer category of risk when a patient is
established to have between 10 and 19% risk over ten years of
developing CVD. It draws on the conceptual and empirical
dimensions of pharmaceuticalisation to evaluate the extent to
which GPs display a pharmaceuticalised approach. The paper
overall finds a stark disparateness between GPs in understandings
of and approaches to CVD prevention. Before presenting the
analysis of the data, the paper sets out the conceptual approach
and reviews the empirical literature on and relevant to CVD
pharmaceuticalisation in the next two subsections.
Pharmaceuticalisation
How can the prescribing practices of GPs in the above context be
analysed sociologically? In this section, the paper sets out the
conceptual and analytical framework the paper draws on.
Pharmaceuticalisation is a sociological process that is defined
by Williams et al. (2011: 711) as the “transformation of human
conditions, capacities or capabilities into opportunities for
pharmaceutical intervention”. Pharmaceuticalisation relates to
and builds on the older concept of medicalisation—which is a
broader process whereby social problems come to be defined and
treated as medical conditions (Conrad, 2007). It is possible for
pharmaceuticalisation to occur with or without medicalisation.
Unmedicalised forms of pharmaceuticalisation occur largely
outside of traditional medical spheres and/or without any
change in or application of a new diagnostic category. Drugs,
such as Adderall for example, have been shown to be used beyond
their intended medical usage (to treat Attention Deficit
Hyperactivity Disorder) and outside of prescription for the
purposes of cognitive enhancement and stimulation (Vrecko,
2015; see also; Coveney et al., 2011). Medical professionals,
medical settings and diagnosis are excluded from
unmedicalised forms of pharmaceuticalisation. This appears to
be of greater interest to Williams et al. (2011), reflecting the
broader distinction between pharmaceuticalisation of this type
and the concept of medicalisation (and thus the uniqueness of
pharmaceuticalisation) (Williams et al., 2017).
However, it is important to be clear that these authors do not
only limit their conceptualisation of pharmaceuticalisation to this
focus. They discuss how pharmaceuticalisation can occur beyond
traditional medical spheres, but also within. The focus on
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pharmaceuticals in and of themselves as analytic entities is a
significant contribution of pharmaceuticalisation across both
medicalised and unmedicalised forms (Coveney et al., 2011:
387; Williams et al., 2017). In this regard, these same authors
have more recently argued that the “value of
pharmaceuticalisation. . . is not solely to do with those
instances which extent beyond medicalisation but also those
occurring within medicalisation” (Coveney et al., 2019: 269).
Considering the scale of the use of pharmaceuticals prescribed
by medical professionals, which in England includes 48% of the
population taking at least one prescribed medicine in the last
week (Moody and Mindell, 2017), the utility of the concept of
pharmaceuticalisation is clearly far greater if it can incorporate
pharmaceuticalisation within as well as beyond traditional
medical spheres.
Where medicalisation and pharmaceuticalisation occur
together, pharmaceuticalisation is occurring within traditional
medical spheres and/or where new or widening diagnostic
categories are interlinked with widening pharmaceutical
deployment. However, where a more medicalised form of
pharmaceuticalisation appears to be occurring, utilising the
conceptual dynamics of pharmaceuticalisation to analyse the
case rather than medicalisation will reflect the primacy of
pharmaceuticals within diagnostic transitions, decision-making
or even where developments surrounding pharmaceuticals can be
shown potentially to drive medicalisation (e.g., through industry
attempts to ‘sell sickness’ and create conditions that can be treated
using pharmaceuticals). When drugs are central analytic entities,
even where medicalisation is also occurring, the greater intensity
and specificity of focus of pharmaceuticalisation on
pharmaceuticals themselves and the actors which shape their
availability, deployment or consumption means that
pharmaceuticalisation is the stronger framework (Coveney
et al., 2011: 387; Williams et al., 2017).
This discussion should show the reader how
pharmaceuticalisation can occur in or outside of the clinical
encounter, alongside or beyond medicalisation. In contrast to
instances of pharmaceuticalisation occurring without
medicalisation, the expansion of pharmaceuticalisation in the
primary prevention of CVD is defined in terms of and facilitated/
necessitated by biomedical risk testing. Medical professionals are also
the gatekeeper to accessing the treatment. This necessarilymeans that
any subsequent drug treatment occurs in and from medical settings
and interactions. Alongside the potential for the deployment of
statins, CVD prevention also includes advice about lifestyle
change, such as advice on exercise, diet, smoking, potentially in
the place of a statin. However, this paper uses the conceptual and
empirical dimensions of pharmaceuticalisation because, in the
prevention of CVD, once a patient’s level of risk has been
established, the central and most salient decision to be made is
about whether to initiate statins—or, in other words, whether the
patient is to become pharmaceuticalised or not and how this occurs.
As will be exploredmore in the next section, this paper examines how
the composition of different knowledge, treatment perspectives, and
values possessed by GPs shapes the extent to which they have a
pharmaceuticalised approach to CVD prevention that they then
bring to consultations with patients.
Reviewing the Literature
This subsection now turns to review the empirical research
conducted on pharmaceuticalisation, with a specific focus on
CVD pharmaceuticalisation. There is a vast body of empirical
research exploring the six potential empirical dimensions of
pharmaceuticalisation set out by Williams et al. (2011). These
are the redefinition and construction of health problems as a
having a pharmaceutical solution; pharmaceutical regulation; the
role of media; patients, consumers, and identities; the use of drugs
for non-medical and enhancement purposes; and pharmaceutical
futures (see Gabe et al., 2015). These six dimensions can be viewed
as delineating a variety of actors and subprocesses that operate as
part of a broader network known as the ‘pharmaceutical regime’
and as providing criteria upon which to judge which actors are
driving (or indeed preventing/constraining/provoking resistance
to) pharmaceuticalisation and its extent.
The empirical interests of this paper relate particularly to the
fourth dimension of pharmaceuticalisation pertaining to patients,
consumers, identities, and the micro-level deployment and use of
pharmaceuticals. This dimension draws on the long history
within medical sociology concerned with providing voice to
lay understandings and experiences (Britten, 1996; Calnan,
1987). It encourages analysis of patient and particularly
consumer identities, understandings and use of
pharmaceuticals (Dew et al., 2015). Both in (but also beyond)
the study of pharmaceuticalisation, there is a large body of
research on the understandings of and decision-making by
patients specifically about statins (and subsequent treatment
pathways) and associated understandings of cholesterol and
risk assessment (Culpit et al., 2020; Farrimond et al., 2010;
Gale et al., 2011; Jovanovic, 2014; Polak, 2016; Saukko et al.,
2012). Polak (2017), for example, notes the complex web of
norms and morals that individuals balance in deciding
whether to become pharmaceuticalised through analysing
identity construction and the morality of taking statins.
However, as a prescribed medicine doctors have long been
important in decision-making about statins1. They are, in other
words, necessarily an important part in whether a patient becomes
pharmaceuticalised. However, research concerned with
pharmaceuticalisation has yet failed to analyse the different ways
that professionals might understand or approach discussions with
patients about statins and the potential impacts of this on
pharmaceuticalisation. Consumerist behaviour amongst patients
seems particularly limited in the context of preventative medicine
(where a patient is ‘at risk’ rather than presently unwell) (Will and
Weiner, 2015). Broader work also suggests continuing trust, albeit
conditional in nature, by patients in professionals (Calnan andRowe,
2008). In these respects, it is necessary to attend to professional
approaches to and understandings of pharmaceuticalisation and
how they interact with patients and subsequently shape
pharmaceuticalisation. Whilst Williams et al. (2011) do
acknowledge that professional expertise retains a certain level of
importance in the decision-making of patients, this dimension,
1However, see Will and Weiner (2015) for discussion of a failed attempt to make
the drugs available over-the-counter.
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however, is primarily oriented towards patients as consumers in the
process of pharmaceuticalisation. Consequently, within
pharmaceuticalisation studies less is known about other
subprocesses and actors involved in decision-making about drugs
and how this might shape (medicalised) pharmaceuticalisation. The
role of professional expertise in decision-making about drugs,
including statins, requires empirical attention.
GPs’ work is discursively informed by a range of knowledge,
values, and multiple understandings of and approaches to
pharmaceutical treatments that GPs possess and bring into
consultations with patients. In this regard, and in the context
specifically of CVD prevention, GPs seem to hold different
understandings of ‘appropriate’ levels of risk in primary
prevention. Gale et al. (2011), have suggested that, even in
relation to prior guidelines and risk thresholds, GPs differed in
their understandings of the appropriate level of risk at which to
initiate preventative treatment. The guideline at this time suggested
≥20% but Gale et al., show how some GPs preferred to start at 15%
and others at 30%. GPs in other research have also seemingly varied
in perspective on the appropriateness of the level of risk (Barfoed
et al., 2015). In addition, Pollock and Jones (2015) have argued that to
appropriately understand and position CVD pharmaceuticalisation
it must be analysed relative to other therapeutic pathways that can be
adopted instead or alongside pharmaceuticals (particularly lifestyle
change). However, how doctors understand and approach the
relative benefits of the therapeutic landscape has not been
analysed in relation to pharmaceuticalisation. This said, Manca
(2018) is one of few examples of pharmaceuticalisation
scholarship engaging with professional understandings, narratives,
and approaches. This research suggests different orientations
amongst and a certain degree of anxiety by some medical
professionals towards pharmaceuticalisation, particularly where
public uncertainty and controversy exists, and the role of the
pharmaceutical industry generally in the production of
knowledge. How these aspects might relate specifically to CVD
pharmaceuticalisation is unclear, however.
This paper examines how the composition of different
knowledge, treatment perspectives, and values as possessed by
GPs shapes the extent to which they have a pharmaceuticalised
approach to CVD prevention. Reflecting these notions, the
research question at the centre of this paper is: how do GPs
understand the ≥10% primary prevention category and the utility
of statins, and what shapes if and how have they have been
implementing guidance about this level of risk?
METHOD
Qualitative Interviewing
The data analysed in this paper is from 20 semi-structured
interviews with GPs collected in late 2015 and through 2016.
In-depth qualitative interviewing is perhaps the most widely used
method in qualitative research and is in the most basic sense, a
conversation oriented at exploring an individual’s account of
social phenomena (Green and Thorogood, 2004: 79–81). The
emphasis in in-depth qualitative interviewing is on the
interviewee’s perspective and their account of lived experience
(Seidman, 2006: 9–10). This allows for rich detailed answers and
descriptions that offer crucial insight into what the participant
views as important about the social phenomenon under study.
These aspects mean that qualitative interviewing was an
appropriate method to use to explore the perspectives and
understandings of GPs about CVD prevention, their lived
experience of the implementation of the ≥10% primary
prevention risk category and approaches to decision-making
about statins.
It is important to note that the interview data represents what
GPs say about how they approach the prescription of statins,
rather than necessarily what they do in practice. Debates exist
about the kinds of knowledge claims that can be made from this
kind of interview data. It has been suggested that data derived
from qualitative interviewing provides idealised accounts that are
not necessarily relatable to what a person actually believes or how
they behave (Murphy et al., 1998: 105). Equally there is an issue of
whether meanings presented in an interview are ever stable and in
some way representative of a verifiable internal (perspectives,
beliefs) or external (actions taken) reality (Dingwall, 1997: 38;
Murphy and Dingwall, 2003). Interviews are thus seen by some as
context specific performances involving a degree of impression
management. Others, however, suggest that accounts by
interviewees can meaningfully be both resource for analysis
and topic of analysis (Hammersley and Atkinson, 2007:
97–98). In terms of the aims of this paper, the researchers
were interested in the understandings and perspectives of GPs,
rather than the actualities of clinical consultations (as a way to
begin to address the gap in knowledge about
pharmaceuticalisation relating to the role of medical
professionals). This paper, as such, does not wish to infer that
what GPs say they do or say they believe can be said to map
necessarily onto what they actually do in practice.
The decision to use semi-structured interviewing rather than
unstructured interviewing reflects the conceptual foundations of
the project and the specific dimension of pharmaceuticalisation
and associated research question the research team wished to
analyse. In this regard, the research team already had a set of
topics that were important to address. As with Coveney, 2010
(91–92) there was concern also that using a completely
unstructured approach might mean neglecting certain topics of
salience to understanding the dimension of
pharmaceuticalisation under study. Semi-structured
interviewing, however, also afforded the interview process a
degree of flexibility to explore further topics of interest as they
emerged, allowing participants the chance to present what they
believed to be important. The semi-structured interviews were
conducted by the lead author using a topic guide. All participants
signed a consent form prior to the interview taking place which
was used to assert that they were aware of the nature of the
research (based on a participant information sheet), right to
withdraw, consent to audio recording, and the way data
derived from the interview would be used. All interviews were
anonymised during the transcription phase (meaning that
information that might lead to identification was removed/
redacted and every name and location were anonymised). The
interview data was then analysed thematically using Braun and
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Clarke’s (2006) six phase model. Coding and theme formation
were conducted primarily by the lead author, but this was
discussed with and agreed by the second author. A third
researcher also examined coding and theme formation, thus
enhancing the internal reliability of the project by building in
an inter-observer consistency. The analysis of GP data was guided
by interest in the ways in which GPs understand the latest NICE
CVD guideline and statins, as well as how they approach,
understand, and report contributing to the decision-making of
patients. Though theoretically and empirically
pharmaceuticalisation has neglected the role of medical
professionals, wider theorising and empirical work suggests
that medical professionals must be brought back into focus to
understand decision-making surrounding drugs more fully,
particularly because such decision-making is a shared activity.
Ultimately three overarching themes were established. These
themes were also further honed to include subthemes with the
primary goal of increasing clarity and particularly allowing for
emphasis on distinct thematic positions apparent in the talk of
GPs to emerge.
Ethics, Access and Sampling
Relevant ethical and research governance approvals for a broader
project that this paper forms part of was granted in 2015 by the
University of Kent and the NHS. Following this, access to GP
interviewees for the study was negotiated in one Clinical
Commissioning Group (CCG) in the south of England. Whilst
it might have improved the external validity of the research (as
well as potentially adding a comparative element) to have
collected data in two or more CCGs, evidence also exists to
suggest that GPs are heterogenous and individualistic even in the
age of clinical practice guidelines (Armstrong, 2002; Spyridonidis
and Calnan, 2011). A relationship was established with a member
of the CCG’s board who displayed particular interest in the topic.
This board member, who was also a GP, acted as a gatekeeper to
accessing GP interview participants. An email advertisement was
sent to every GP working within the CCG. The response was
initially muted, but several further emails were sent over a period
of nine months (in line with ethical approval). A purposive
sampling approach was taken. At the most basic level,
qualification to participate was based on being a GP currently
working within the CCGwith an aim of recruiting an even split of
male and female GPs. In particular, the researcher set out to
establish a sample diverse in terms of levels of clinical experience.
The rationale here was that differences in clinical experience
might shape how GPs approached the use of guidelines (due to
the clash between clinical experience and guidelines noted in
other research discussed above). A sampling frame was
established relating to years of clinical experience (early or
later career), with the aim of interviewing between seven and
ten GPs with ten or less years clinical experience as a GP. The
sampling also ultimately benefitted from elements of snowballing
with GPs on several occasions recommending and asking
particularly younger colleagues if they would consider
participating. Ultimately twenty GPs were interviewed. Twelve
were female and eight were male, with seven having ten or less
years of experience.
RESULTS
The thematic analysis of the interviews with GPs is presented
in three overarching themes: Use of Guidelines, Treatment
Perspectives, and Evaluations of Relevant Information. As
such, the analysis begins with an examination of the
manner in which GPs perceive and use guidelines and
knowledge generated and disseminated via EBM particularly
compared to emphasis placed on the importance of their own
clinical experience and discretion. The paper then examines
how this relates to how GPs reported they were implementing
relevant components of CG181. It then discusses differential
perspectives on and understandings of treatment. This
is analytically distinct from the first theme in that it
captures differing perspectives and preferences about
treatment options as relates to, for example, the moral
aspects present in the talk. The final theme presented in the
paper highlights how ethical and personalised patient
evaluations feature in the presentation of ‘relevant’
information to patients. It is argued overall that disparate
approaches by GPs to CVD pharmaceuticalisation across these
themes can be identified.
USE OF GUIDELINES
In this first theme, the paper focuses on how GPs perceive and
approach the use of NICE guidelines, and the specific form of
knowledge it embodies. From the data analysis, it very clearly
emerges that the ways in which GPs engage with the ≥10%
primary prevention risk category reflects existing
understandings of and engagements with EBM. The analysis is
divided into two thematic positions.
Positive about NICE Guidance
The first thematic position that emerged from analysis of the
data pertaining to GP perspectives on NICE guidelines was of
acceptance of and need to conform practice to EBM in
medical practice. This position reflects the perceptions
primarily of GPs who were judged to have spoken
positively about the role of NICE guidance in
contemporary primary care. GPs within this thematic
position here can be thought of as accepting of the logic of
EBM. NICE guidelines, though as part of a broader decision-
making process, were seen by GPs here as the “gold standard”
(GP3) and the best available and should be followed (where
appropriate).
Acceptance of the logic of EBM, and as such, NICE guidelines
more specifically, was rooted in several aspects.
We are working in a very broad sense. We are
gatekeepers, we never have a clue what is coming
through the door and we have to know a little bit
about everything. I think that is actually quite
difficult. . . If we didn’t have some guidance in
certain areas to follow it would be quite tricky to
have a uniform approach to things (GP13).
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This quote from GP13, a younger GP with a lower number of
years of experience, suggests that NICE guidelines are necessary
because of the nature of general practice and the need for
uniformity in practice. This is echoed by GP5, this time a very
experienced GP, who stresses how difficult general practice might
be and specifically managing voluminous evidence.
I am thoroughly in favour of NICE and I am very glad
about their existence; and I think it would be very
difficult to practice with the huge amount of
evidence in modern medicine, the huge wealth of
data, if you didn’t have NICE there to do it. So yes
thoroughly in favour of NICE guidance (GP5).
The importance of uniformity was also stressed by GP6, an
experienced and older GP, with an emphasis this time on
protecting patients from dangerous practice.
I see it as trying tomake sense of a sophisticatedmodern
health service and trying to make sure that nobody is
doing anything that sort of are crazy or even dangerous.
The evidence these guidelines are based on is the best
evidence we have so we should try to follow it (GP6).
Trust in NICE by GPs taking this position was also important.
GP7, a relatively young and less experienced GP for example,
trusted NICE as ‘the experts’ as a way to navigate (humble)
concerns about their own lack of speciality and related ability to
keep up with and make sense of the underpinning or developing
research evidence.
As a GP I don’t think I have any particular expertise and
I have a lot of faith in the people who develop the
guidelines. . . as having more knowledge about a
particular topic than I do, do you know I want
mean? So you know, whilst it is quite nice to have
free range to do whatever you like, I’m happy that the
people who develop the guidelines are in inverted
commas experts and as such they are generating
good advice if that makes sense (GP7).
GPs who spoke in this way were also generally positive about
the latest primary prevention category and the widened
availability of statins because of this. GP3, for example, one of
the least clinically experienced GPs in the sample, felt that
targeting patients at lower levels of risk would get people on a
statin earlier who would need one eventually anyway.
I mean somebody who has got a 20% risk and had it for
a few years is likely to have really furred up arteries. If
you can get them on a statin at [lower] risk a couple of
years earlier, then that can only be beneficial (GP3).
More specifically, the population level approach necessitated
in the treatment of risk of CVD (and indicative of EBM due to
being rooted in RCT data and disseminated by guidelines) was
positively viewed. This kind of GP saw the change as having
potentially beneficial impacts on the levels of cardiovascular
events in the population and which necessarily shaped
considerations of benefit even in individual consultations. This
sentiment was clearly articulated by GP18, also younger and with
only a few years of clinical experience, who compared statins to
vaccines because they have population level benefit (rather than
solely or even primarily, an individual benefit).
My outlook on the usefulness of these [drugs]. . . does
include consideration of population level benefits. And I
suppose for me statins are like vaccines to a certain
extent (GP18).
In addition, though concerns about the adverse effects of
statins had featured prominently in professional and popular
discourse surrounding this guideline, these GPs (though aware of
these debates) generally saw statins to be a safe drug, largely
reflecting their views of the underpinning evidence and the logic
of EBM. GP12, this time an experienced GP, here argues that
statins are safe drugs and that people convinced statins were
harming them had increased likelihood of CVD morbidity,
despite contrary evidence.
I’ve seen significant morbidity from people who are
convinced that statins are doing them harm. I think
illogically. Very occasionally you see significant harm
from a statin, but very rarely in my experience and that
is supported by the available evidence that we have
(GP12).
Negative about NICE Guidance
However, other GPs stressed a greater emphasis on the negative
aspects of NICE guidance. Important here were notions that
NICE guidelines were dictum from above and actively devalued
or had the potential (if a doctor too rigidly attempted to follow
them) to devalue individual discretion and clinical autonomy.
This was used as a basis to criticise the value of EBM. GP8, a very
experienced GP, for example, spoke of professional experience as
like an additional sense, but that this was being devalued by the
mechanisms of EBM.
. . .training and clinical experience has got to count for
something hasn’t it? Increasingly the experience side of
it is being devalued. Erm before long they will be
training monkeys to do our job, or certainly
machines. If you take the sort of sixth sense out of it
then you know what are we there for? (GP8).
Due to this devaluing of clinical experience, EBM as embodied
by guidelines was for this type of GP of limited acceptability. One
of the most experienced GPs, GP1, also emphasised, for example,
the importance of professional experience and knowledge in
terms of the quality-of-care patients receive.
. . .my personal view is that the particular and so-called
evidence-based medicine on which guidance is based
has limited value in that I think that evidence-based
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decision making should take into account evidence-
based medicine in the sense of NICE, but also the
patients’ wishes. . . but also long term clinical
experience and professional knowledge (GP1).
It was also suggested that NICE guidelines did not necessarily
translate well into real world consultations and were created with
some sort of ideal patient in mind rather than the one in front of
them. GP8, for example, directly challenges this and also
articulates the fear of and resentment about potentially being
sued for not following them.
I do not necessarily think that they are always in the
individual patient’s benefit. Erm so I will discuss it with
the individual patients but we won’t necessarily adhere
to them. . . It’s not so much that I object to their use,
what I object to is the one size fits all. . .Erm so you
know if they were just guidelines it would be fine but
they sort of but they are marketed as very dogmatic
rules that could lead to us being sued (GP8).
GP1 meanwhile suggested there might be reasons for not
trusting guidelines and those that produce them due to evidence
not being available (seemingly echoing well known concerns
about the influences of commercial influences on what data is
shared and published).
I think they [NICE] are probably responding to research
evidence here—but only some of the research is
published and available (GP1)
This GP continues by rejecting the level of risk justifying the
intervention, and as such, the population level logic for
prescribing statins to a wider number of people as
recommended by the guideline.
I think in this case it is a [question] of at what point they
are recommended. And actually whether we are treating
a lot of people unnecessarily to reduce one event. So the
case of numbers needed to treat. . .if we are having to
treat 200 with the view of reducing one cardiovascular
event or separate vascular incidents, you know a lot of
people get side effects with statins therefore it would be
questionable at this level. . . I think I’d have to see a
stronger argument for benefit before subjecting patients
to likely risk of side effects. . . . I think we are broadly
beginning to fiddle around the edges of benefit. Kind of,
we have tackled the low hanging fruit (GP1).
In the second half of this extract, it is also clear that this GP
problematises the likelihood of increased instances of side effects
for individuals who may gain little from taking the drugs. In this
way, this GP seemed to judge their own professional knowledge
and experience to be more reliable than the NICE clinical practice
guideline. Meanwhile, here GP17, a GP also with many years of
clinical experience, discusses how the lower risk threshold, from
their perspective, is potentially too low because, again, the risk of
side effects do not seem to be justifiable relative to benefits to
individual patients. Interestingly, again, there is also a negative
perception relayed about the distinction between overarching
population risk prevention, and those who create these strategies,
and the individual patient sat in front of the GP.
. . .in my mind the numbers needed to treat kind of
balance better at the 20% than they do at the 10%. You
have to treat vastly more people to reduce one person
from having a heart attack or a stroke. So you know
obviously in terms of the population as a whole you
know if you are a strategist, a health strategist you see
this as a very viable sensible thing. . ..But as a GP you
kind of think ‘ughhh’ when you know that a good 20%
do get statins side effects, whether they recognise them
or not—in terms of fatigue, energy levels, ability to
think, muscle aches and so on and so forth (GP17).
For this kind of GP then, in contrast with their colleagues above,
there was a clear clash between what guidelines intended
(operating with population level focus) and the real patient sat
in front of them. Themost salient point here is that guidelines were
thought to devalue professional discretion, experience, and
knowledge, but due to the individualised experiences and needs
of patients, these aspects were in fact perceived as inherent
necessities. There was evidence of negative perceptions about
those who create guidelines when compared to the realities of
consultations with patients and the work done by GPs.
Only one GP within the sample had been completely ignoring
the lowered primary prevention threshold—and thus totally
resisting the pharmaceuticalisation of patients. However, other
GPs with critical attitudes towards guidelines had been discussing
risk testing and reduction with patients who had a risk level
between 10 and 19% mostly because they felt legally pressured to
record they had done so or (more commonly) duty bound as part
of facilitating informed patient decision-making to conduct risk
testing and discuss treatments options with patients. As is
explored later in the paper, however, there was sometimes
emphasis by the type of GP with these perspectives on
engaging with lifestyle changes rather than utilising a statin to
lower risk, which was partially rooted in dissatisfaction with a
population level, collectivised rationale, and the greater
individualised benefits from lifestyle changes than from a statin.
TREATMENT PERSPECTIVES
The analysis of the data also suggested that there were three different
perspectives about the therapeutic landscape (statins and/or lifestyle
change) in the ≥10% risk category. GPs held disparate opinions,
often quite distinct from the specifics of the guideline about the best
approach to the treatment of CVD risk. Whilst this partially
connects to and reflects the above discussions about use of and
approaches to guidelines themselves, there were also aspects that
emerged from the data that were distinct from these considerations
and stand as important analytical insights on their own—most
notably relating to the moral qualities of treatment.
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Statins and Lifestyle Changes Together
Some GPs (the largest group) saw the ≥10% threshold in terms of a
unified therapeutic landscape and emphasised the necessity for
(typical) patients of making lifestyle changes prior to and
subsequently alongside taking a statin. GPs here in this category
broadly focused on the preventative benefits that would come from
a unified treatment approach. This is exemplified by GP3
describing their approach to consultations with patients.
I frame it as ‘there are some things that will help bring
risk down, lifestyle changes, and medications we can
offer that will help, including a statin.’...Part of a suite of
things that we are trying to do (GP3).
GP18 similarly emphasises how statins can help lower risk but
not instead of lifestyle changes, stating that it is not ‘lifestyle
versus statins’.
I think, I suppose, I don’t view it as lifestyle versus
statins. . .I will always say, you know, my phrase always
goes along the line of well we should be thinking about
starting a statin which will help to lower your risk of a
heart attack and stroke, but this isn’t instead of making
lifestyle changes (GP18).
GP10, a younger and less experienced GP, meanwhile suggests
that starting a statin might make people complacent about
making lifestyle changes because they think the statin will
protect them. There is also a subtle emphasis by GP10 on the
moral need for patients to make lifestyle changes rather than
relying on a statin, evidenced by the use of the word ‘complacent’.
I think for most people I think it is important that we
tackle that [lifestyle] side of things first. Because I think
they can be complacent. Some people think if we put
then on a statin they think ‘oh that is fine’ (GP10).
Interestingly, as this quote from GP7 indicates, there was a
sense of professional responsibility to encourage lifestyle changes
(e.g., stopping smoking) rather than only prescribing drugs
evident in the talk of this sort of GP.
From my perspective if someone smokes there is hardly
any point in someone taking a statin, you know what I
mean?. . . You might make a tiny dent in their risk
comparative to what stopping smoking will do. . . I’m
not always saying have a statin, I’m saying lets see what
happens if we you know we can stop the
smoking (GP7).
Superiority of Lifestyle Change
Another slightly smaller group of GPs suggested that they actively
attempted to promote lifestyle change in place of a statin where
risk level was between 10 and 19%. It was not necessarily that
these GPs would not offer or prescribe a statin at this threshold
(particularly when deferring to a patient centred model of care),
but these GPs reported that they advised and emphasised to
patients the benefits of lifestyle changes to a much greater extent
than they promoted a statin.
This category of GP was more clearly motivated by a moral
imperative surrounding looking after one’s own health rather
than relying on drugs. This is evident here where GP17
emphasises ‘reliance on tablets’ at the expense of healthy
living. This was a GP who, importantly, had spoken (as can be
seen in the previous section) quite negatively about the
underpinning rationale of the guideline. The connection here
between problematising EBM and preferences for lifestyle change
can be seen.
Of course, one of the biggest difficulties with [statins],
um we have become a nation that relies on tablets. . ..
The risk of statins is that people carry on living the same
lifestyle of over-eating of over-drinking, not doing
exercise (GP17).
GP20, a very experienced GP, makes a similar point,
emphasising that drugs are increasingly seen as the answer to
problems of lifestyle.
My problem is that it is just. . . giving out pills for
everything, rather than, you know, it is just that people
need to eat better, exercise more (GP20).
GP11, meanwhile, emphasises interestingly (particularly as a
GP with only a limited number of years of experience) that while
guidelines suggest that patients should take a statin, it was a
superior approach to avoid the drugs. This leaves the impression
that the unified approach to treatment contained in the guideline
is morally inferior to reducing risk via lifestyle changes alone.
I’d say you know there are guidelines that suggest you
should be on some medicines now because of the
cholesterol and the diet and that kind of thing. But I
generally say we want to prevent that if we can (GP11).
Statins Independently
The smallest group of GPs reported placing significantly more
emphasis in their framing to patients on the importance of a
statin relative to the benefits from lifestyle change. There was a
clear acceptance by GPs in this subset of the ≥10% risk category,
its necessity and that it was a risk level that required the
application of treatment. And in this way, the drugs were a
morally neutral application of the best available evidence. GP6
spoke, for example, about the clear evidence-based benefits of a
statin and compared this to their understanding of the evidence
based benefits of lifestyle changes.
You see there’s some evidence that even a low dose statin is
extremely effective in prevention. So even if a patient is not
very tolerant and they are taking a low dose of something
they are still getting an awful lot of protection. Erm it’s
much less clear, apart from smoking, how much say
weight loss, or exercise has an impact. They are
complementary but independent of too (GP6).
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GP12 here also suggested that the structure of society was set
up in such a way that facilitated and perpetuated unhealthy
lifestyles, and statins were a necessary (if unfortunate) solution
to this. This seemed to partially make patient use of statins
morally neutral in the view of this GP, whilst also meaning it
was necessary and legitimate for them to prescribe (providing a
sort of moral absolution for the GP too).
Well lifestyle choices have a huge impact, do a lot of
exercise, doesn’t smoke, healthy lifestyle you know.
Then they are much less likely to get cardiovascular
disease. But that is influenced so much by culture,
structure of society, which is nothing to do with their
GP. Lifestyle change is hard to make and keep up. How
important is it? Well it is hard to assess actually and to
keep up. For a GP. . . verging on the impossible. . .
Statins, I can do (GP12).
The three positions identified in this theme clearly show
distinct approaches to and understandings of the treatment of
CVD risk in the 10-19% risk category. In other words, GPs were




Though the above theme captures much of importance in terms
of the approach preferred by GPs within the context of shared
decision-making about the therapeutic landscape at the 10–19%
level of risk, further qualifications and complexities emerged in
the data. In the data analysed, it was apparent that treatment
decision-making in the ≥10% risk category was also reflective of a
number of ‘evaluations’ that GPs reported that they conducted
prior to and within the context of consultations. These
evaluations informed what was considered to be relevant
information and its presentation to patients.
Ethical Evaluations
It was clear that GPs in the sample undertook a variety of
evaluations about what was considered relevant information to
a patient that can be thought of as ethical evaluations. For
example, GP20, who, as seen above, problematised the
widened primary prevention category, was concerned about
whether a ≥10% primary prevention threshold was an
appropriate threshold for intervention and thus should be
considered ‘relevant information’ to the patient. In this data
extract, GP20 expressed a concern that telling patients about
their risk at this threshold would cause patients unnecessary
stress, worry, and potentially contradict the medical ethical
principle of nonmaleficence (the intentional avoidance of harm).
I’ve found it hard to even talk to patients. . .. Some of
them will worry. . . why would I want to make them
worry when I don’t really believe they are significantly
at risk of an event? (GP20).
A further ethical dilemma surrounding evaluation of what
constitutes relevant information also emerges in a different and
slightly more obscure way—in terms of whether GPs decided to
tell patients that the ≥10% category represented (at the time of
data collection) a recent change. Indeed, GPs had varying
orientations to and rationales for whether they explained to
patients that this threshold represented a change in policy.
Whilst this may only be a small element of some consultations
with patients, what is important here is the disparities between
GPs in their approaches again. Differential framing by GPs here
means that patients have more or less access to relevant
understandings/perspectives/knowledge, which in turn may
feature in how they understand risk and therapeutic options.
It was seen by some GPs as relevant information, and for others,
as something unimportant to patient-centred care and decision-
making, despite the controversial nature of the change and the
potential pertinence of information, for example, that less than
two years previously patients would not have been offered a
statin. For some GPs, such as GP2, an experienced GP, a changing
guideline was not really seen as relevant to patient-decision
making and that patients would not be interested in this fact.
TD: Do patients know that something has changed in
terms of NICE guidance?
GP2: I’m not sure they really understand there has been
a shift here.
TD: So it’s not part of your conversations?
GP2: I don’t bring that up. I don’t say look it used to be
20% but we’ve brought this down. I just say that look
you fall into the threshold where we would normally
offer cholesterol lowering medication.
This perspective was mirrored by GP18 who did not think the
older guidance remained relevant to patients in the present.
I do not say anything about changing guidelines to
them, I suppose I don’t tend to see it as particularly
relevant to them what the previous guideline used to
say. I think that the current guidelines are the ones that
we are following and they are the best practice at the
moment (GP18).
For GPs thinking in this way, it was only seen as necessary to
explain to patients who had been told during a previous
assessment that CVD risk and/or cholesterol were
unproblematic, thus causing them to question whether their
health had become worse.
For GP13, it was apparent that there was a conscious decision not
to talk about the fact that the threshold had changed because they did
not want to give patients room to protest against interventions (as
seen above, this GP positively viewed NICE guidelines).
I personally only say that if they were someone who
previously. . . told that they were fine. . . I wouldn’t say
that has recently changed. It would just give them more
reason to protest (GP13).
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Other GPs, such as GP14, an experience GP, however, had
more actively discussed the change of threshold with
patients—with a suggestion that it was ethically necessary to
provide this information.
You know a year ago or however long it was, two years
ago we were saying it was 20% and I think that
immediately sets a different tone to the conversation
really doesn’t it (GP14).
It was clear, as such, in the talk of certain GPs, that by
presenting information to patients about the changed
threshold, having evaluated that this was necessary, there was
an explicit acknowledgement that this information could shape
decision-making about statins, and as such, was ethically
necessary in terms of making patients aware of surrounding
debates. It was also important ethically in that it facilitated
informed decision-making in the face of potential patient
confusion. Whilst the importance of this element of GP
practice is perhaps unlikely to be important in a long-term
sense, there was a clear disparity apparent here in GP practice
in the 18-24 months between guideline publication and data
collection.
Personalised Evaluations
GPs also placed differential personalised emphasis on
particular elements of a patient’s lifestyle considered
problematic, such as smoking, as was evaluated as relevant
to the individualised context of the patient. Some GPs also
seemed to draw on what they knew about the patient’s overall
life. GP15 suggested that for many people, including at 10%, it
is hard to make lifestyle changes due to various social
arrangements and commitments, reflecting the structure of
society—thus prompting this GP to offer a statin earlier in the
process and more forcefully to patients. For GP15, an
experienced GP, there is a clear focus here on what might
be achievable for patients based on the particular
circumstances of the patient, whilst also filtering this
advice through personal perceptions and understandings of
treatment, in this case, as a GP who believes strongly in the
utility of statins.
I still think that people should try to make lifestyle
changes but you’ve also got to be realistic sometimes
when they are working long hours or something, and
thus I often just say ‘we should really strongly think
about a statin because your risk falls within the
problematic range’. . . You can lecture people until
you are blue in the face about exercise, diet,
whatever, but realistically they are living lives that
they are struggling with (GP15).
For patients without additional issues such as comorbidities
or a strong family history of CVD, risk level relative to
therapeutic pathway was also personalised. In essence, for
some GPs in the sample, the closer the patient was to 20%
the more likely they were to emphasise the need for a statin,
whilst closer to 10% risk they would advise patients with more
emphasis on lifestyle change. This is particularly interesting
when compared to the actualities of the guideline where there
is no distinction made between risk reduction strategies at
different risk levels within the overall threshold. For GP13, the
way in which emphasis was given to particular therapeutic
pathways seemed to reflect, as such, a personalised evaluation
of the level of risk.
I definitely do think the figuremakes a difference to how
I would behave in the consultation. . . if they were on
19% I would be much more keen to talk seriously with
them into a statin. If they were 11% then I would
probably have a more half hearted effort (GP13).
GP7 had a similar perspective. This GP reported trying to
calculate risk level if patients were successful with lifestyle
changes, and if this was still going to be high within the risk
threshold then suggested that statins might be initiated earlier in
the process. Interestingly GP7 elsewhere suggested a treatment
preference for a balance of lifestyle and statins to prevent CVD,
which is consistent with the comments here. However, how
quickly statins were introduced reflected personalised
evaluation of risk.
I tend to look at the numbers. . .I don’t tend to say to
patients I don’t think this will work. I say this is what I
think is feasible in terms of lifestyle change, this is what
your score will be if professionals happens and it’s up to
them. I might say I think that’s reasonable because we
might be able to do well here, but if it is still gonna be
well above 15 then I tend to say ‘we’ll try to make these
changes, but we can start you on a statin if you want to
now rather than waiting’ (GP7).
DISCUSSION
This paper has explored how GPs possess a range of
knowledge, values, and multiple understandings of and
approaches to pharmaceutical treatments in the context of
the latest CVD prevention clinical practice guidance. Thus far,
reflecting the way Williams et al. (2011) have constructed their
conceptual framework of pharmaceuticalisation, research on
their fourth dimension of pharmaceuticalisation has primarily
explored the consumerist behaviours and pharmaceutical
identities of patients in the process of pharmaceuticalisation
(Dew et al., 2015; Will and Weiner, 2015). Consequently,
within the pharmaceuticalisation literature less is known
about other actors involved in clinically situated decision-
making about drugs and how this might shape
pharmaceuticalisation. Statins are a drug that need to be
prescribed, and where pharmaceuticalisation is occurring it
does so in a medicalised form. It is important, as such, to
analyse the understandings of and approach to the
prescription of statins by those who have the authority to
prescribe them. It is true that it cannot be known from the data
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presented what the impacts are of the different understandings
and approaches of GPs across the themes on if patients become
pharmaceuticalised. However, it has shown how GPs’ role in
decision-making about statins is informed and shaped by a
range of knowledge, values, and multiple understandings of
and approaches to pharmaceutical treatments that GPs possess
and bring into consultations with patients. These aspects have
not been analysed in the pharmaceuticalisation literature
before. As will be shown below, GPs can be argued to sit
somewhere on a spectrum of pharmaceuticalised
understandings of and approaches to CVD prevention.
Where they sit on this spectrum reflects the combinations
or dominance of certain knowledge and its use, treatment
perspectives and preferences, and a range of moral and ethical
values.
Research suggests that GPs do not receive and utilise
knowledge and evidence disseminated through clinical
practice guidelines in uniform ways (Carlsen, 2010; Hansen
et al., 2016; Spyridonidis and Calnan, 2011). This seems to
reflect conceptions of medical professional identity unique to
the GP, with a significant emphasis on clinical discretion,
experience and autonomy (Carlsen and Norheim, 2005) and
a pronounced distinction between themselves and specialists
that emphasises patient centred and holistic care (Checkland
et al., 2008; Hansen et al., 2016). Clinical experience, and the
associated existing cognitive familiarity with, for example, a
particular treatment, seem to remain crucial and explains
reluctance to follow clinical practice guidelines uncritically.
The data analysis in this paper shows similarly that a
problematising orientation taken towards NICE guidelines
by a minority group of GPs was evident in the data, a
subtheme which is broadly in line with sociological
literature concerned with the understandings and
implementation of clinical practice guidelines (Spyridonidis
and Calnan, 2011). A rejection of the collectivised population
level logic underpinning NICE guidelines and the preventative
use of statins was compatible with a lifestyle focus (and the
perception of the supposedly greater individualised benefit) for
these GPs. Experience level and number of years in clinical
practice was also important here. Greater experience levels
generally coalesced with negative perspectives about NICE
guidelines and greater comfort in practicing outside of the
guideline.
However, a larger group of GPs did see the value of the
knowledge produced and disseminated through guidelines, in
a way not dissimilar to that articulated by McDonald et al.
(2009), and this was reflected in the fact that most of the GPs
interviewed had been attempting to implement the guideline.
The divide between GPs concerning clinical practice guidelines
evident in the data has not necessarily been articulated in the
same way in other studies, although when looking at the
literatures on professionalism and professional identity
overall divergent positions are apparent. The acceptance of
the guidance, and thus of the logic of EBM was associated with
trust in NICE. The importance of trust for actors other than
only patients (and their trust in health professionals) in
healthcare emerges here then as indicated by other
scholarship (Brown and Calnan, 2016; Douglass and
Calnan, 2016). Trust was placed in NICE and their
evaluative activity particularly to bridge over aspects of
uncertainty and where knowledge constraints were
acknowledged/evident.
Overall, differential approaches to and understandings of
clinical practice guidelines are important to understandings of
pharmaceuticalisation. Certainly, the development of a new
guideline that creates an opportunity for pharmaceuticals to be
more widely available and used, does not mean that this will be
how GPs will interpret and approach the prescription of
drugs—or even use/abide by them at all (GP1 had been
ignoring the guideline, for example). The type of
understandings of and approaches possessed by a GP relating
to guidelines are one important aspect when examining the extent
to which GPs have a pharmaceuticalised understanding of/
approach to CVD prevention.
Pollock and Jones (2015) have argued that the analysis of
CVD pharmaceuticalisation must be contextualised relative to
the broader therapeutic landscape. Sufficiently appreciating
this point necessarily means engaging with the cultural context
within which decision-making about drugs is taking place
(Gabe, 1990)—particularly surrounding notions of
individual responsibility for health. In the data, GPs had
different understandings of the moral qualities of the drugs
and of lifestyle change as treatment options. At the centre of
the issue here was the potentially ‘unnecessary’ utilisation of
pharmaceuticals where healthy lifestyle practices could be
adopted to mitigate risk and a sense of their own
professional responsibility to encourage healthy lifestyles.
For a number of GPs there was a pronounced narrative of
lifestylism similar to that described by Hansen and Easthope
(2007) which diminished the desire to pharmaceuticalise
patients. Some of these GPs described themselves, as such,
as preferring to medicalise participants through discussions of
biomedically informed advice about lifestyle changes to
improve health. Where GPs viewed statins as morally
neutral, less or no medicalisation of this type was preferred.
Interestingly then, where GPs described a preference for
increased medicalisation or pharmaceuticalisation this was
often at the expense of the other process. Polak (2017)
meanwhile highlights the complex moral positions patients
take on statins use. Similarly, the findings presented above
confirm that GPs also possess disparate understandings that
reflect moral positions pertaining to perceptions of individual
responsibility for health that influence treatment perspectives.
GPs themselves, of course, do not exist in a social vacuum and
the line between medical knowledge and social emphasis on
individual responsibility is blurred (Hansen and Easthope,
2007). The different positions of GPs are important to
appreciate though because GPs’ perspectives (at least as far
as they allow them to emerge in consultations) are likely to be
one important aspect in the configuration of patients’ own
moral positioning on treatment—although this requires
further empirical exploration. Certainly, again, that GPs
have their own moral perspectives on different treatment
pathways is important for sociological understanding of
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pharmaceuticalisation. Whilst guidelines (embodying EBM)
are supposedly the neutral dissemination of the best available
evidence, GPs’ clearly bring a range of perspectives to the
decision-making process that may contradict what guidelines
recommend. This has not been noted in the
pharmaceuticalisation literature before now.
It is also clear that decision-making about statins in the
≥10% risk category is discursively informed by a range of
other values that GPs possess and bring into consultations
with patients. Clinch and Benson (2013) show how GPs
attempt to order and present information to patients in
ways that related to the specific circumstances of the
patient. Similar aspects were found in the data analysed
above—for example, as related to individual patient risk
level within the broader risk threshold. This data also
mirrors older research that has shown that doctors in the
context of older guidelines varied in the level of risk that they
felt was sufficient to begin interventions to prevent CVD
(Gale et al., 2011). As above, the different values that GPs
hold and bring to consultations can contradict clinical
practice guidelines, and in this sense, also shape the
extent to which their understandings and approaches can
be said to be pharmaceuticalised.
Concluding Comments: A Spectrum of
Pharmaceuticalised Understandings and
Approaches
Looking across these themes, reflecting the ways in which
knowledge, treatment perspectives and moral values were
combined and drawn on by individual GPs, GPs arguably
exist on a spectrum of how pharmaceuticalised they are in
their approach to the primary prevention of CVD. Those on
one end of the spectrum can be characterised as the most
pharmaceuticalised in their understandings and approaches.
These GPs were the most positive and emphasising of the
benefits of statins within the ≥10% risk category. GPs towards
this end of the spectrum saw the drugs as morally neutral,
superior within the therapeutic landscape, and their widening
usage the reflection of the best available evidence. These GPs
were often also positive about guidelines and EBM more
generally. There were no examples in the data of GPs
critical of EBM but who viewed statins positively at the 10-
19% risk level. On the other end of the spectrum, however, are
those GPs that can be argued to be the least
pharmaceuticalised in their approach. Indeed, one GP at
the polar extreme was completely ignoring the 10%-19%
threshold of risk, reporting that they did not necessarily
conduct risk testing or discuss lifestyle changes with
patients in this risk category. More generally, GPs at this
end of the spectrum often reluctantly discussed with patients’
risk in this category, with a very heavy emphasis on making
lifestyle changes instead of initiating a statin, and raised
ethical (such as ‘needlessly’ worrying patients) and moral
issues. Indeed, statins had the most significant moral
baggage for this group of GPs—and emphasis was placed
on not using drugs to treat problems of lifestyle. This
group often were also the most emphasising of the
importance of individual professional experience/
knowledge and the most critical of EBM (see, for example,
extracts from GP17). Distinctive from these GPs are those
who are partially pharmaceuticalised in their understanding
and approach, but often viewed lifestyle changes as necessary
and/or importantly prior to initiating statins. In this regard,
GPs in the middle of the spectrum displayed some concern
about patients taking a statin without making changes where
necessary to lifestyle behaviours on health and moral levels.
However, GPs more in the centre of the spectrum often
practiced closely to the guideline and also displayed trust
in NICE. GPs in the centre of the spectrum were also often
younger and/or less experienced professionals. Lesser clinical
experience and the greater prominence of EBM within their
medical education compared with older colleagues was likely
to be important in practice being most clearly guided by the
guideline.
It seems likely in a context of continuing trust, albeit
conditional trust, in professionals (Calnan and Rowe, 2008)
and muted consumerist tendencies in CVD prevention (Will
and Weiner, 2015) that disparate professional approaches to
and understandings about pharmaceuticalisation will have
differential impacts on patient decision-making. Nevertheless,
further research is required to establish the precise actualities of
the impacts of differential pharmaceuticalised approaches to
CVD prevention by GPs, and their positioning on the spectrum,
in the configuration of patient understandings and identities
relating to CVD prevention and taking statins. Where a patient
and a GP hold (initially) distinct perspectives on
pharmaceuticalisation it may be of particular analytical
interest to establish how important the pharmaceuticalised
approach of a GP positioned at the polar ends of the
spectrum is in this context and the associated impacts on
pharmaceuticalisation.
Overall, the disparate approaches evident in the data
analysed suggest that GPs cannot be considered universally
and uncritically to be a driving force of CVD
pharmaceuticalisation within the ≥10% risk category. The
value of this paper is that it provides clear indication of the
disparate understandings of and approaches to
pharmaceuticalisation displayed by GPs and the array of
factors that feature in how they understand statins and
report approaching decision-making about statins. This
paper fills an important lacuna in knowledge about
pharmaceuticalisation as conceptualised by Williams et al.
(2011). In this regard, this paper has shown how even in the
context of clinical practice guidelines recommending
widening pharmaceuticalisation, GPs’ use of the knowledge
embodied by guidelines is not uniform.
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